DOCSLIB.ORG

Advancing E400 Protein Therapeutics Optimising Therapeutic Potential During Research and Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Book by Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 February 19th Location: Radisson Blu Hotel, Frankfurt, Germany and save up to Advancing E400 Protein Therapeutics Optimising Therapeutic Potential During Research and Development Advancing Protein Therapeutics focuses on overcoming the key Hear 24 world leading protein challenges in optimising therapeutic and drug-like qualities, therapeutic experts and will help you to maximise the commercial potential of your protein therapeutic pipeline. • Dr Graham Molineux, Executive Director, Research, Amgen n Learn the latest techniques for engineering protein therapeutics • Dr Tom Kost, Director, Biological Reagents and Assay to improve PK/PD and immunogenicity, with an overview from Dr Development, GlaxoSmithKline Graham Molineux, Executive Director of Research at Amgen. • Dr Lutz Jermutus, Senior Director, Technology, MedImmune n Get an update on the latest methodologies for expression and • Dr Scott Glaser, Director of Antibody Therapeutics, production of therapeutic proteins with presentations from Dr Biogen Idec Tom Kost, Director of Biological Reagents and Assay Development • Dr Michael Doyle, Group Leader, Protein Therapeutics for GSK and Dr Trevor Wilkinson, Associate Director of Protein Discovery Biochemistry and Biophysics, Bristol-Myers Sciences at MedImmune Squibb Research and Development • Dr Chichi Huang, Research Fellow, Centocor n Dr Michael Doyle, Group Leader of Protein Therapeutics (Johnson & Johnson) Discovery at Bristol-Myers Squibb, outlines the application of a • Dr Andy Nixon, Vice President, Lead Discovery and thermodynamic solubility assay during lead selection Biochemistry, Dyax Corp • Dr Trevor Wilkinson, Associate Director of Protein n Understand how Medimmune are developing novel biologics Sciences, MedImmune to target less accessible cell surface antigens, with a detailed • Prof Arne Skerra, Professor of Biological Chemistry, description from Dr Lutz Jermutus, their Senior Director of Technische Universitat Munchen Technology. • Dr Josi Holz, Chief Medical Officer,Ablynx n Dr Scott Glaser, Director of Antibody Therapeutics at Biogen • Dr Lars Abrahmsen, Chief Scientific Officer,Affibody • Dr Julian Bertschinger, Co-founder and Chief Executive Idec, outlines the very latest developments in the construction of Officer,Covagen bispecific antibodies, including preclinical examples • Dr Arnd Steuernagel, Chief Scientific Officer,ScilProtein n Discover how Centocor (Johnson & Johnson) are using Fc-Fusion • Dr Christian Zahnd, Chief Executive Officer, proteins to enhance therapeutic potential and extend half-life Molecular Partners • Dr Christina Furebring, Vice President Research & Development, Alligator Bioscience • Dr Samantha Cobb, Chief Executive Officer,AdAlta INTERACTIVE WORKSHOPS Tuesday 20th April • Dr Jeffrey Cleland, Chief Executive Officer, Versartis • Dr Kendall Mohler, Senior Vice President, Research & Intellectual Property in Therapeutic Proteins 9.30 - 12.30 Development, Trubion Dr Antonio Maschio, Partner • Dr Nico Mertens, Senior Director of Antibody Engineering, Edwards Angell Palmer & Dodge Innovations LLP Biotecnol • Prof Christian Heinis, Group Head, EPFL Challenges in the Clinical Development 13.30 - 16.30 • Dr Kevin FitzGerald, Chief Executive Officer, of Biological Medicines f-star GmbH Cecil Nick, Vice President (Biotechnology), PAREXEL Consulting • Dr Andreas Hohlbaum, Chief Technology Officer, Pieris AG • Dr Dominik Escher, Managing Director and Vice President Media Partners R&D, ESBATech • Dr Karyn O’Neil, Chief Scientific Officer,Centyrex, Johnson & Johnson Ventures To register: www.protein-therapeutics.com • Email [email protected] Tel +44 (0) 203 141 8700 • Fax +44 (0)20 7222 2685 Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 | Location: Radisson Blu Hotel, Frankfurt, Germany Optimising Therapeutic Potential During Research and Development Enhancing Protein Therapeutics to Deliver Business Growth Advancing protein therapeutics through the clinic and into the market is fraught with difficulties. So why make it any tougher? Invaluable feedback on your protein therapeutics The agenda for this meeting has been designed with direct The quality and rate of innovative research and development input from most of the successful innovative companies in the proteins therapeutics sector has increased dramatically in the last few years. As part of the Biorbis mission to developing protein drugs today. Companies like Pfizer, Merck, accelerate progress and encourage dialogue, we encourage MedImmune, Biogen Idec, Amgen, GSK, Johnson & attendees to present a poster. Johnson, Bristol-Myers Squibb and Roche, have all given Presenting a poster is free of charge to all registered delegates. Please note that poster displays may not be used frank and honest assessments of principle challenges facing for sales or marketing purposes, and all poster abstracts are protein therapeutic developers. subject to approval by the conference organisers. Just tick on the booking form or inform us when registering. We’ve collated this information into an agenda, and collected Contact Richard Lumb at [email protected] some of the world’s leading experts in the field, to provide you for more details with valuable knowledge and first-hand experiences that you simply cannot get elsewhere. Who Should Attend Advancing Protein Therapeutics is an elite meeting of Hear the world’s brightest minds talking about: international scientists and research leaders from the major pharmaceutical companies and large, medium and small n Improving the PK/PD characteristics of your protein biotechs. Directors and Heads of Biologics, Protein Engineering, R&D, Chief Executive and Scientific therapeutics, including modulation of half–life and Officers, research leaders and scientists will all benefit matching of pharmacokinetics to clinical requirements. and have the opportunity to debate issues at the cutting edge of the sector. n Enhancing production of proteins for therapeutic application Register now and speak to the most innovative biotechs in the sector and forward-thinking research establishments. Make and for preclinical studies using novel expression the most of opportunities for face-to-face dialogue during systems. our interactive and networking sessions and converse with the other attendees as well as the skilled speaker faculty. Just n Improving the therapeutic effectiveness of protein be ready to talk about your work and don’t forget to bring therapeutics, including efficacy and tissue penetration. plenty of business cards. n Expanding the alternative scaffold portfolio to include completely novel antibody-alternatives. Biorbis in on an unrelenting mission to deliver scientific meetings to the n The very latest developments in advancing multivalent business and research community that will accelerate progress and protein therapeutics towards the clinic ultimately benefit patients. Our focus is on discovering what makes a difference to your n How to design protein therapeutics that target less research or business, and working with you to design highly accessible cell surface antigens relevant, cutting-edge agendas with content delivered by globally recognised experts and leaders in the field. n An interactive panel discussion addressing the future of We create an environment that encourages open dialogue, frank discussion, generation of ideas and exchange of protein therapeutics, including overcoming challenges information that will help to advance medical science and in progressing to the clinic and an assessment of the most improve your research or grow your business. promising alternative scaffolds. www.biorbis.com To register: www.protein-therapeutics.com • Email [email protected] Tel +44 (0) 203 141 8700 • Fax +44 (0)20 7222 2685 Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 | Location: Radisson Blu Hotel, Frankfurt, Germany CONFERENCE DAY ONE: 21st April 2010 08.30 Registration, coffee and networking PRODUCING PROTEINS FOR THERAPEUTIC APPLICATION 09.00 Chairman’s Opening Remarks Dr Scott Glaser, Director, Antibody Therapeutics, Biogen Idec 13.45 BacMam Transduction: A Versatile Approach for Protein Expression IMPROVING PHARMACODYNAMICS / n Utilising BacMam viruses for gene delivery and protein PHARMACOKINETICS expression as an alternative to transient transfection n Flexibility of BacMam virus gene delivery system in assay development and potential in protein production for pre- 09.05 KEYNOTE ADDRESS: Engineering Protein Therapeutics to clinical studies. Improve PK/PD and Immunogenicity Dr Tom Kost, Director, Biological Reagents & Assay Development n Evolution of protein therapeutics to enhance pharmacology GlaxoSmithKline profiles n Addressing safety concerns during protein development 14.15 Transient Production of Recombinant Proteins in Dr Graham Molineux, Executive Director, Research, Amgen Inc Mammalian Cells and its Role in Supporting Drug Discovery Programs n Applications of transient mammalian expression systems 09.35 Engineering Kunitz Domains to Extend Plasma Half-Life n Expression of recombinant antigens and antibodies using PEGylation and Protein Fusions n Case studies describing support of Drug Discovery Programs n Overview of the design features of a human Kunitz domain Dr Trevor Wilkinson, Associate Director, Protein Sciences scaffold library MedImmune n Identification of engineered potent and selective serine protease inhibitors using a human Kunitz domain scaffold
Recommended publications
  • Wo2015188839a2

    Wo2015188839a2

    Downloaded from orbit.dtu.dk on: Oct 08, 2021 General detection and isolation of specific cells by binding of labeled molecules Pedersen, Henrik; Jakobsen, Søren; Hadrup, Sine Reker; Bentzen, Amalie Kai; Johansen, Kristoffer Haurum Publication date: 2015 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Pedersen, H., Jakobsen, S., Hadrup, S. R., Bentzen, A. K., & Johansen, K. H. (2015). General detection and isolation of specific cells by binding of labeled molecules. (Patent No. WO2015188839). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/188839
  • Fig. 1C Combination Therapy of Tumor Targeted ICOS Agonists with T-Cell Bispecific Molecules

    Fig. 1C Combination Therapy of Tumor Targeted ICOS Agonists with T-Cell Bispecific Molecules

    ( (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/30 (2006.01) A61P 35/00 (2006.01) kind of national protection av ailable) . AE, AG, AL, AM, C07K 16/28 (2006.01) A 6IK 39/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07K 16/40 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/EP20 18/086046 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 20 December 2018 (20. 12.2018) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available) . ARIPO (BW, GH, 17209444.3 2 1 December 2017 (21. 12.2017) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant (for all designated States except US): F. HOFF- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 124, 4070 Basel (CH).
  • Design and Screening of Degenerate-Codon-Based Protein Ensembles with M13 Bacteriophage

    Design and Screening of Degenerate-Codon-Based Protein Ensembles with M13 Bacteriophage

    Design and Screening of Degenerate-Codon-Based Protein Ensembles with M13 Bacteriophage by Griffin James Clausen B.S. Biomedical Engineering University of Minnesota – Twin Cities, 2012 Submitted to the Department of Biological Engineering in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Biological Engineering at the Massachusetts Institute of Technology February 2019 © 2019 Massachusetts Institute of Technology. All rights reserved. Signature of Author: ____________________________________________________________ Griffin Clausen Department of Biological Engineering January 14, 2019 Certified by: ___________________________________________________________________ Angela Belcher James Mason Crafts Professor of Biological Engineering and Materials Science Thesis Supervisor Accepted by: ___________________________________________________________________ Forest White Professor of Biological Engineering Graduate Program Committee Chair This doctoral thesis has been examined by the following committee: Amy Keating Thesis Committee Chair Professor of Biology and Biological Engineering Massachusetts Institute of Technology Angela Belcher Thesis Supervisor James Mason Crafts Professor of Biological Engineering and Materials Science Massachusetts Institute of Technology Paul Blainey Core Member, Broad Institute Associate Professor of Biological Engineering Massachusetts Institute of Technology 2 Design and Screening of Degenerate-Codon-Based Protein Ensembles with M13 Bacteriophage by Griffin James Clausen Submitted
  • Strategies and Challenges for the Next Generation of Therapeutic Antibodies

    Strategies and Challenges for the Next Generation of Therapeutic Antibodies

    FOCUS ON THERAPEUTIC ANTIBODIES PERSPECTIVES ‘validated targets’, either because prior anti- TIMELINE bodies have clearly shown proof of activity in humans (first-generation approved anti- Strategies and challenges for the bodies on the market for clinically validated targets) or because a vast literature exists next generation of therapeutic on the importance of these targets for the disease mechanism in both in vitro and in vivo pharmacological models (experi- antibodies mental validation; although this does not necessarily equate to clinical validation). Alain Beck, Thierry Wurch, Christian Bailly and Nathalie Corvaia Basically, the strategy consists of develop- ing new generations of antibodies specific Abstract | Antibodies and related products are the fastest growing class of for the same antigens but targeting other therapeutic agents. By analysing the regulatory approvals of IgG-based epitopes and/or triggering different mecha- biotherapeutic agents in the past 10 years, we can gain insights into the successful nisms of action (second- or third-generation strategies used by pharmaceutical companies so far to bring innovative drugs to antibodies, as discussed below) or even the market. Many challenges will have to be faced in the next decade to bring specific for the same epitopes but with only one improved property (‘me better’ antibod- more efficient and affordable antibody-based drugs to the clinic. Here, we ies). This validated approach has a high discuss strategies to select the best therapeutic antigen targets, to optimize the probability of success, but there are many structure of IgG antibodies and to design related or new structures with groups working on this class of target pro- additional functions.
  • International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU

    International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU

    ( 2 (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 39/42 (2006.01) C07K 16/10 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, C07K 16/08 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 19/033 995 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 24 May 2019 (24.05.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available) . ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/676,045 24 May 2018 (24.05.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: LANKENAU INSTITUTE FOR MEDICAL TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, RESEARCH [US/US]; 100 Lancaster Avenue, Wyn- KM, ML, MR, NE, SN, TD, TG).
  • 2010.01) C07k 14/74 (2006.01

    2010.01) C07k 14/74 (2006.01

    ( (51) International Patent Classification: su 215 123 (CN). LIN, Yanni; F2, Building B20, Sangt- C07K 19/00 (2006.0 1) C12N 5/0783 (20 10.01) ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu C07K 14/74 (2006.01) A61K 35/1 7 (2015.01) 215123 (CN). ZHENG, Xiaocui; F2, Building B20, Sangt- C12N 15/62 (2006.01) A61P 35/00 (2006.01) ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). KONG, Hongmei; F2, Building B20, Sangt- (21) International Application Number: ian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu PCT/ CN2020/ 1081 16 215123 (CN). WANG, Wenbo; F2, Building B20, Sangtian (22) International Filing Date: Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215 123 10 August 2020 (10.08.2020) (CN). FENG, Aihua; F2, Building B20, Sangtian Street 218, Suzhou Industrial Park, Suzhou, Jiangsu 215 123 (CN). (25) Filing Language: English (74) Agent: J. Z. M. C. PATENT AND TRADEMARK LAW (26) Publication Language: English OFFICE (GENERAL PARTNERSHIP); YU, Mingwei, (30) Priority Data: Room 5022, No. 335, Guo Ding Road, Yang Pu District, 201910746355.8 13 August 2019 (13.08.2019) CN Shanghai 200433 (CN). PCT/ CN20 19/124321 (81) Designated States (unless otherwise indicated, for every 10 December 2019 (10. 12.2019) CN kind of national protection av ailable) . AE, AG, AL, AM, (71) Applicant: CURE GENETICS CO., LTD. [CN/CN]; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, Biobay A4-5 10, Xinghu Street 218, Suzhou Industrial Park, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Suzhou, Jiangsu 215 123 (CN).
  • WO 2018/144999 Al 09 August 2018 (09.08.2018) W ! P O PCT

    WO 2018/144999 Al 09 August 2018 (09.08.2018) W ! P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/144999 Al 09 August 2018 (09.08.2018) W ! P O PCT (51) International Patent Classification: Lennart; c/o Orionis Biosciences NV, Rijvisschestraat 120, A61K 38/00 (2006.01) C07K 14/555 (2006.01) Zwijnaarde, B-9052 (BE). TAVERNIER, Jan; c/o Orionis A61K 38/21 (2006.01) C12N 15/09 (2006.01) Biosciences NV, Rijvisschestraat 120, Zwijnaarde, B-9052 C07K 14/52 (2006.01) (BE). (21) International Application Number: (74) Agent: ALTIERI, Stephen, L. et al; Morgan, Lewis & PCT/US2018/016857 Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing ton, D.C. 20004 (US). (22) International Filing Date: 05 February 2018 (05.02.2018) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/454,992 06 February 2017 (06.02.2017) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: ORIONIS BIOSCIENCES, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 275 Grove Street, Newton, MA 02466 (US).
  • Affinity Chromatography (AC)

    Affinity Chromatography (AC)

    Affinity Chromatography (AC) 1 Affinity Chromatography (AC) • Principles of AC • Main stages in Chromatography • How to prepare Affinity gel - Ligand Immobilization - Spacer arms – Coupling methods – Coupling tips • Types of AC • Elution Conditions • Binding equilibrium, competitive elution, kinetics • Industrial Examples: Protein A/G for Therapeutic proteins • Future Considerations 2 What is affinity chromatography? Affinity chromatography is a technique of liquid chromatography which separates molecules through biospecific interactions. The molecule to be purified is specifically and reversibly adsorbed to a specific ligand The ligand is immobilized to an insoluble support (“matrix”): resin, “chip”, Elisa plate, membrane, Western, IP (immuneprecipitation), etc Introduction of a “spacer arm” between the ligand and the matrix to improve binding Elution of the bound target molecule a) non specific or b) specific elution method 3 What is it used for? Monoclonal and polyclonal antibodies Fusion proteins Enzymes DNA-binding proteins . ANY protein where we have a binding partner!! 4 Designing and preparing an affinity gel Choosing the matrix Designing the ligand - Spacer arms Coupling methods 5 Ligand Immobilization Ligand + Activating agent + Matrix Activated Immobilised matrix ligand 6 Designing the ligand Essential ligand properties: interacts selectively and reversibly with the target Carries groups which can couple it to the matrix without losing its binding activity Available in a pure form 7 Steric considerations & spacer arms Small ligand (<1,000) Risk of steric interference with binding between matrix and target molecule Often need spacer arm but watch out for Spacer arm adsorption to the spacer! 8 Design of spacer arms Alkyl chain Real risk of unspecific interactions between H H spacer and target molecule O O Hydrophilic chain Risk of unspecific interactions greatly O H reduced No coupling reaction will use 100% of the available binding sites.
  • EURL ECVAM Recommendation on Non-Animal-Derived Antibodies

    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies

    EURL ECVAM Recommendation on Non-Animal-Derived Antibodies EUR 30185 EN Joint Research Centre This publication is a Science for Policy report by the Joint Research Centre (JRC), the European Commission’s science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. EURL ECVAM Recommendations The aim of a EURL ECVAM Recommendation is to provide the views of the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) on the scientific validity of alternative test methods, to advise on possible applications and implications, and to suggest follow-up activities to promote alternative methods and address knowledge gaps. During the development of its Recommendation, EURL ECVAM typically mandates the EURL ECVAM Scientific Advisory Committee (ESAC) to carry out an independent scientific peer review which is communicated as an ESAC Opinion and Working Group report. In addition, EURL ECVAM consults with other Commission services, EURL ECVAM’s advisory body for Preliminary Assessment of Regulatory Relevance (PARERE), the EURL ECVAM Stakeholder Forum (ESTAF) and with partner organisations of the International Collaboration on Alternative Test Methods (ICATM). Contact information European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3) Address: via E.
  • Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold

    Generation of Novel Intracellular Binding Reagents Based on the Human Γb-Crystallin Scaffold

    Generation of novel intracellular binding reagents based on the human γB-crystallin scaffold Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I-Biowissenschaften der Martin-Luther-Universität Halle-Wittenberg Institut für Biochemie und Biotechnologie von Ewa Mirecka geboren am 17. Dezember 1976 in Gdynia, Polen Table of contents Table of contents 1. INTRODUCTION.........................................................................................................1 1.1 Monoclonal antibodies as a biomolecular scaffold..........................................................1 1.2 Binding molecules derived from non-immunoglobulin scaffolds.....................................3 1.2.1 Alternative protein scaffolds – general considerations............................................................ 3 1.2.2 Application of alternative binding molecules ........................................................................... 6 1.3 Affilin – novel binding molecules based on the human γB-crystallin scaffold................... 6 1.3.1 Human γB-crystallin as a molecular scaffold........................................................................... 6 1.3.2 Generation of a human γB-crystallin library and selection of first-generation Affilin molecules ................................................................................................................................ 8 1.4 Selection of binding proteins by phage display ...................................................................
  • Monobodies and Other Synthetic Binding Proteins for Expanding Protein Science

    Monobodies and Other Synthetic Binding Proteins for Expanding Protein Science

    Reviews Protein Science DOI 10.1002/pro.3148 Monobodies and Other Synthetic Binding Proteins for Expanding Protein Science Fern Sha,1,4 Gabriel Salzman,1 Ankit Gupta1,2 and Shohei Koide1,2,3* 1Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, USA 2Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA 3Department of Biochemistry and Molecular Pharmacology New York University School of Medicine, New York, NY 10016, USA 4Present address, Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20148, USA *Correspondence to: Shohei Koide, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA. E-mail: [email protected] Abstract Synthetic binding proteins are constructed using non-antibody molecular scaffolds. Over the last two decades, in-depth structural and functional analyses of synthetic binding proteins have improved combinatorial library designs and selection strategies, which have resulted in potent platforms that consistently generate binding proteins to diverse targets with affinity and specificity that rival those of antibodies. Favorable attributes of synthetic binding proteins, such as small size, freedom from disulfide bond formation and ease of making fusion proteins, have enabled their unique applications in protein science, cell biology and beyond. Here, we review recent studies that illustrate how synthetic binding proteins are powerful probes that can directly link structure and function,
  • WO 2018/098356 Al 31 May 2018 (31.05.2018) W !P O PCT

    WO 2018/098356 Al 31 May 2018 (31.05.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/098356 Al 31 May 2018 (31.05.2018) W !P O PCT (51) International Patent Classification: co, California 94124 (US). DUBRIDGE, Robert B.; 825 A61K 39/395 (2006.01) C07K 16/28 (2006.01) Holly Road, Belmont, California 94002 (US). LEMON, A61P 35/00 (2006.01) C07K 16/46 (2006.01) Bryan D.; 2493 Dell Avenue, Mountain View, California 94043 (US). AUSTIN, Richard J.; 1169 Guerrero Street, (21) International Application Number: San Francisco, California 941 10 (US). PCT/US20 17/063 126 (74) Agent: LIN, Clark Y.; WILSON SONSINI GOODRICH (22) International Filing Date: & ROSATI, 650 Page Mill Road, Palo Alto, California 22 November 201 7 (22. 11.201 7) 94304 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Langi English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/426,069 23 November 2016 (23. 11.2016) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/426,077 23 November 2016 (23. 11.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicant: HARPOON THERAPEUTICS, INC. KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, [US/US]; 4000 Shoreline Court, Suite 250, South San Fran MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, cisco, California 94080 (US).